Were I a lawyer and I am not, Mr. Stockboy muses.
1. I'd first establish in facts, there is clear evidence generic firms are benefiting from taking 43% from at best 10% skinny law intention. I'd offer a simple pie chart easy to understand.
2. I'd second establish in facts, the actual percentages of that 43% particularly highlighting Hikma's lion's share of that 43% and how Hikma clearly premeditated its path in the majority of abuse of the skinny law.
3. Now three, I'd connect Hikma as guilty as accused by the premeditated facts. I'd then drive home Hikma's documented intention to exploit to their benefit the non-skinny indication. Spell it out in simple terms how 'How Hikma knew in advance how they could get away with going around the skinny label law.'
4. I'd even quote Judge Du who acknowledged her decision would hurt Amarin's revenues, making it clear the skinny label law is being abused, Amarin has suffered incredible losses, and millions of potential patients are not even benefiting from this life saving drug because Amarin's loss has crippled the firm to such a degree a 600 sales force was terminated and today thousands of physicians still don't know about Vascepa. Meanwhile, Hikma flaunts the intent of the skinny label law and in turn millions of CVD patients don't even know about Vascepa.
5. Taken all the evidence against Hikma, it was clear they promoted and planned, premeditated, and even have led the way making them culpable for its actions and are liable for breaking the intent for the skinny label law.
6. Finally, present the nail in the coffin. A head to head analysis of the Vascepa capsule vs the Hikma so-called generic. Create doubt, lots doubt, and NEVER APPROVED BY THE FDA FOR CVD and any jury despite Hikma's skinny label approval, their generic is in fact an inferior generic which they are selling to the public by an illegal end-around breaking of the skinny label law.
Keep it factual. Keep it simple. lET THE TRUTH PREVAIL. Smear the EPA all over Hikma's face.
